Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048763 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Raynaud's Disease

Interventions

DRUG: Pletal

Sponsor

Otsuka America Pharmaceutical